These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18616509)

  • 1. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
    Juhl-Christensen C; Bomberg M; Melsvik D; Hokland P; Nyvold CG
    Eur J Haematol; 2008 Oct; 81(4):273-80. PubMed ID: 18616509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
    Pabst T; Mueller BU
    Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
    Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
    Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
    Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
    J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
    Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
    Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
    Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
    Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PU.1 and CEBPA expression in acute myeloid leukemia.
    D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
    Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
    Schnittger S; Bacher U; Eder C; Lohse P; Haferlach C; Kern W; Haferlach T
    Exp Hematol; 2011 Jan; 39(1):87-94. PubMed ID: 20888888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexity of miR-223 regulation by CEBPA in human AML.
    Eyholzer M; Schmid S; Schardt JA; Haefliger S; Mueller BU; Pabst T
    Leuk Res; 2010 May; 34(5):672-6. PubMed ID: 20018373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the unfolded protein response in human acute myeloid leukemia.
    Schardt JA; Mueller BU; Pabst T
    Methods Enzymol; 2011; 489():227-43. PubMed ID: 21266233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F; Rajput S; Mandava S; Das BR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
    Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
    Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nature of frequent deletions in CEBPA.
    Fuchs O; Kostecka A; Provaznikova D; Krasna B; Brezinova J; Filkukova J; Kotlin R; Kouba M; Kobylka P; Neuwirtova R; Jonasova A; Caniga M; Schwarz J; Markova J; Maaloufova J; Sponerova D; Novakova L; Cermak J
    Blood Cells Mol Dis; 2009; 43(3):260-3. PubMed ID: 19651529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.